Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 26,823 | 14,240 | 0 | 0 | 0 |
| Cost of Goods | 2,881 | 1,704 | 0 | N/A | N/A |
| Gross Profit | 23,942 | 12,536 | N/A | N/A | N/A |
| Operating Expenses | 416,310 | 402,287 | 378,418 | 335,916 | 316,269 |
| Operating Income | -391,487 | -389,047 | -378,418 | -335,916 | -316,269 |
| Other Income | 39,399 | 157,246 | 21,908 | 6,611 | 14,861 |
| Pre-tax Income | -352,088 | -231,801 | -356,510 | -329,305 | -301,408 |
| Net Income Continuous | -352,088 | -231,801 | -356,510 | -329,305 | -301,408 |
| Net Income Discontinuous | 0 | 0 | 1,961,225 | 1,935 | -110,064 |
| Net Income | $-352,088 | $-231,801 | $1,604,715 | $-327,370 | $-411,472 |
| EPS Basic Total Ops | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 |
| EPS Basic Continuous Ops | -6.33 | -4.23 | -5.90 | -4.77 | -5.02 |
| EPS Basic Discontinuous Ops | N/A | N/A | 32.45 | 0.03 | -1.84 |
| EPS Diluted Total Ops | -6.33 | -4.23 | 26.55 | -4.74 | -6.86 |
| EPS Diluted Continuous Ops | -6.33 | -4.23 | -5.90 | -4.77 | -5.02 |
| EPS Diluted Discontinuous Ops | N/A | N/A | 32.45 | 0.03 | -1.84 |
| EPS Diluted Before Non-Recurring Items | -6.33 | -4.23 | -5.90 | -4.74 | -6.86 |
| EBITDA(a) | $-389,915 | $-381,681 | $-362,229 | $-323,104 | $-311,376 |